Understanding how certain proteins affect liver damage from acetaminophen overdose
Novel proteolytic mechanisms driving pathologic hepatic congestion in drug-induced hepatotoxicity
This study is looking at how a protein called macrophage elastase might help protect the liver from damage caused by too much acetaminophen, with the goal of finding better treatments for people who have taken too much of this common pain reliever.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-11032017 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind liver injury caused by acetaminophen overdose, which is a leading cause of acute liver failure. The team is exploring how a specific protein, macrophage elastase (MMP-12), can help prevent the worsening of liver damage by regulating the production of another protein involved in inflammation. By using advanced experimental techniques and data from patients, the researchers aim to identify new treatment strategies that could improve outcomes for those affected by acetaminophen toxicity.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced acetaminophen overdose or are at risk of acute liver injury due to acetaminophen use.
Not a fit: Patients who have liver damage from causes other than acetaminophen overdose may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from acetaminophen overdose, potentially reducing hospital stays and improving recovery rates.
How similar studies have performed: Previous research has shown promising results in understanding liver injury mechanisms, but this specific approach focusing on MMP-12 is relatively novel.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Luyendyk, James P — Michigan State University
- Study coordinator: Luyendyk, James P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.